RESUMEN
INTRODUCTION: Sickle cell anemia (SCA) is a hematological genetic disorder caused by a mutation in the gene of the ß-globin. Pharmacological treatments will continue to be an important approach, including the strategy to induce fetal hemoglobin (HbF). AREAS COVERED: Here, we analyzed the articles described in the literature regarding the drug discovery of HbF inducers. The main approaches for such strategy will be discussed, highlighting those most promising. EXPERT OPINION: The comprehension of the mechanisms involved in the ß-globin regulation is the main key to design new drugs to induce HbF. Among the strategies, gamma-globin regulation by epigenetic enzymes seems to be a promising approach to be pursued, although the comprehension of the selectivity role for those new drugs is crucial to reduce adverse effects. The low druggability of transcription factors and their vital role in embryonic human development are critical points that should be taken in account for drug design. The guanylate cyclase and the NO/cGMP signaling pathway seem to be promising not only for HbF induction, but also for the protective effects in the cardiovascular system. The association of drugs acting through different mechanisms to induce HbF seems to be promising for the discovery of new drugs.
Asunto(s)
Hemoglobina Fetal , Globinas beta , Humanos , Hemoglobina Fetal/genética , Hemoglobina Fetal/metabolismo , Hemoglobina Fetal/farmacología , Globinas beta/farmacología , Factores de Transcripción , Transducción de SeñalRESUMEN
We present a study performed on 54 unrelated subjects, with and without thalassemic features. Two primer pairs were proposed to perform Sanger sequencing of the complete HBB gene. The bioinformatic analysis was performed taking advantage of the availability of free online tools. In the sample, we found 11 variants, 10 reported, and one novel. Among the variants found, six are clinically important: three encode a premature stop codon [codon 39 (C>T) (HBB: c.118C>T); IVS-II-1 (G>A) (HBB: c.315+1G>A), and one not reported], a double substitution within the same allele [Hb Borås (HBB: c.266T>G) and Hb Santa Giusta Sardegna (HBB: c.282T>C)], and one whose pathogenicity is not yet defined [Hb Fannin-Lubbock I (HBB: c.359G>A)]. Even though the variants Hb Borås and Hb Santa Giusta Sardegna have been described, there is no report of their combined occurrence on the same allele, which could cause hemolytic anemia. Although the p.Leu88Arg and p.Cys93Trp variants do not alter the final length of the protein, the bioinformatic results suggest that there are differences in the tertiary structure of ß-globin genes, mainly affecting helices E and F, being the motifs of interaction with the heme group. The novel variant is a 4 bp insertion that modifies the open reading frame, changing the last amino acid residue and causing a premature stop codon (HBB: c.291-294insGCAC). The variant was associated with ß-thalassemia (ß-thal). Bioinformatic analysis made it possible to predict the consequences that the new variant of the HBB gene caused on the ß-globin tertiary structure.
Asunto(s)
Talasemia beta , Alelos , Codón sin Sentido , Biología Computacional , Humanos , Mutación , Globinas beta/genética , Talasemia beta/genéticaRESUMEN
INTRODUCTION: Folate deficiency is commonly reported in ß-thalassemia. Individuals heterozygous for ß-thalassemia may have higher folate requirements than normal individuals. OBJECTIVES: To document the concentration of serum total folate and its forms in ß-thalassemia heterozygote users (ß-TmU) and nonusers (ß-TmN) of 5 mg folic acid/d; to determine whether folic acid (FA) consumption from fortified foods allows beta-Tm patients, who do not take FA supplements, to meet their dietary folate requirements; and to investigate the association between higher serum unmetabolized folic acid (UMFA) and inflammatory cytokine concentrations. METHODS: Serum total folate and forms were measured in 42 ß-Tm (13 ß-TmU and 29 ß-TmN) and 84 healthy controls. The mononuclear leucocyte mRNA expression of relevant genes and their products and hematological profiles were determined. RESULTS: ß-TmU had higher serum total folate, 5-methyltetrahydrofolate, UMFA, and tetrahydrofolate (THF) compared with ß-TmN. The ß-TmN had lower serum total folate and THF than controls. Plasma total homocysteine (tHcy) was lower in ß-TmU compared with both ß-TmN and controls, while ß-TmN had higher tHcy than controls. ß-TmU had higher IL-8 than their controls while ß-TmN had higher IL-6 and IL-8 than their controls. ß-TmU have higher levels of serum total folate, 5- methyltetrahydrofolate, UMFA, and THF than controls. There was no association between UMFA concentrations and cytokine levels. CONCLUSIONS: Mandatory flour fortification with FA in Brazil may be insufficient for ß-TmN, since they have higher tHcy and lower serum total folate than controls. Furthermore, ß-TmN have higher IL-6 levels than ß-TmU. UMFA was not associated with inflammatory cytokine levels.
Asunto(s)
Citocinas/sangre , Ácido Fólico , Alimentos Fortificados , Heterocigoto , Talasemia beta/sangre , Adulto , Femenino , Ácido Fólico/administración & dosificación , Ácido Fólico/farmacocinética , Humanos , Inflamación/sangre , Inflamación/dietoterapia , Inflamación/genética , Masculino , Persona de Mediana Edad , Talasemia beta/dietoterapia , Talasemia beta/genéticaRESUMEN
ß-Thalassemia (ß-thal) trait is a heterogeneous group of genetic defects leading to decreased ß-globin production, ineffective erythropoiesis, and oxidative stress. The aim is to evaluate the cytoprotective response, at transcriptional and systemic levels, of the variations of global redox balance in ß-thal trait patients. Sixty-six subjects (40 healthy and 26 with ß-thal trait) were analyzed at the Universidad Nacional de Tucumán, Tucumán, Argentina, between 2016 and 2017. The following parameters were evaluated: complete blood count, iron status, hemoglobin (Hb) electrophoresis, Hb A2, thiobarbituric acid reactive species (TBARS), serum catalase (CAT), and superoxide dismutase (SOD) activity, FOXO3a, NRF2, SOD, PRDX2, CAT, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) gene expression. The ß-thal trait group showed a decrease in Hb levels, MCV, and MCH with higher TBARS levels. The SOD activity was significantly increased by 32.0% in ß-thal trait patients respect to the control group. Relative expression of NRF2 was 4.7-fold higher in ß-thal trait than in the control group, while FOXO3a expression was similar in both groups. The SOD, PRDX2, and proinflammatory cytokines transcriptional expression was significantly upregulated in ß-thal trait patients. This is the first study on the genetic regulation of redox balance in ß-thal trait patients in which interesting modifications were observed in the transcript levels of some redox regulators that could be associated with changes in the erythrocyte proteome in this disorder. A better understanding of the pathophysiological mechanisms present in these heterozygous patients would allow adequate therapy in situations such as growth, pregnancy, or high performance sports, favoring a personalized treatment.
Asunto(s)
Estrés Oxidativo , Talasemia beta/sangre , Talasemia beta/genética , Adolescente , Adulto , Anciano , Argentina/epidemiología , Estudios Transversales , Índices de Eritrocitos , Femenino , Regulación de la Expresión Génica , Humanos , Masculino , Persona de Mediana Edad , Oxidación-Reducción , Adulto Joven , Globinas beta/genética , Talasemia beta/epidemiología , Talasemia beta/metabolismoRESUMEN
OBJECTIVE: The purpose of this study was to illustrate the association between vascular endothelial growth factor level and pulmonary artery hypertension in children with ß-thalassemia major. METHOD: This case-control study was conducted on 116 children with ß-thalassemia major; 58 of them had pulmonary artery hypertension. They were compared to 58 healthy children who were age and sex-matched (control group). Serum levels of vascular endothelial growth factor and echocardiographic assessment were done for all children. RESULTS: Vascular endothelial growth factor serum level was significantly higher in children with ß-thalassemia major with pulmonary artery hypertension than in those without pulmonary artery hypertension, as well as in control groups (p<0.001). Vascular endothelial growth factor serum level had a significant positive correlation with pulmonary artery pressure and serum ferritin, as well as a significant negative correlation with the duration of chelation therapy. Logistic regression analysis revealed that elevated vascular endothelial growth factor (Odd Ratio=1.5; 95% Confidence Interval, 1.137-2.065; p=0.005) was an independent risk factor of pulmonary artery hypertension in such children. Vascular endothelial growth factor serum level at a cutoff point of >169pg/mL had 93.1% sensitivity and 93.1% specificity for the presence of pulmonary artery hypertension in children with ß-thalassemia major. CONCLUSION: Elevated vascular endothelial growth factor serum level is associated with pulmonary artery hypertension in children with ß-thalassemia.
Asunto(s)
Hipertensión Pulmonar/sangre , Factor A de Crecimiento Endotelial Vascular/sangre , Talasemia beta/sangre , Adolescente , Edad de Inicio , Análisis de Varianza , Estudios de Casos y Controles , Niño , Ecocardiografía Doppler , Femenino , Humanos , Hipertensión Pulmonar/fisiopatología , Masculino , Curva ROC , Valores de Referencia , Factores de Riesgo , Esplenectomía , Estadísticas no Paramétricas , Factores de Tiempo , Talasemia beta/fisiopatologíaRESUMEN
Acute lymphoblastic leukemia (ALL) has been suggested as a long-term complication in patients with ß-thalassemia major (ß-TM). A 12-months-old male patient was diagnosed with ß-TM. The patient required a blood transfusion weekly for 2 years. At the age of 4 years, a splenectomy was performed due to massive splenomegaly and frequent transfusion requirements. The histopathological analysis of the spleen revealed extensive hemosiderosis. ALL-L1 with the T immunophenotype and without central nervous system (CNS) involvement was diagnosed when the patient was 5 years old, and treated with anti-leukemic combination chemotherapy and CNS radiotherapy. The patient completed 24 months of treatment and has been in complete remission for 7 years, without long-term adverse events.
RESUMEN
Over the last 43 years, surveys of over 200,000 subjects in Jamaica have identified ß-thalassemia (ß-thal) mutations. In most, these genes were detected at birth in patients with sickle cell-ß-thal and so the prevalence and distribution would not be influenced by subsequent clinical course. There were two newborn populations, 100,000 deliveries in the corporate area between 1973-1981 and 84,940 in south and western Jamaica between 2008-2016. A third population, which derived from the Manchester Project in central Jamaica, screened 16,612 secondary school children, aged predominantly 15-19 years, and identified 150 students with the ß-thal trait and 11 with sickle cell [Hb S (HBB: c.20A>T)]- or Hb C (HBB: c.19G>A)-ß-thal. The latter patients may have been subject to symptomatic selection, but this should not have affected those with ß-thal trait. Of the 24 different molecular mutations, ß0-thal genes accounted for 10.0-27.0% of these groups and most common was IVS-II-849 (A>G) (HBB: c.316-2A>G). Of the ß+ mutations, seven subjects had severe genes with low levels of ß chain synthesis but the majority were benign mutations in the promoter region. The -29 (A>G) (HBB: c.-79A>G) mutation dominated in the newborn study in Kingston, similar to experiences in Guadeloupe and African Americans but the -88 (C>T) (HBB: c.-138C>T) mutation was more common among school students in central Jamaica. Caribbean populations are genetically heterogeneous but variations within different parts of Jamaica is of potential importance for prenatal diagnosis and genetic counseling. This information may also be useful among the large Jamaican diaspora.
Asunto(s)
Pruebas Genéticas/estadística & datos numéricos , Mutación , Talasemia beta/genética , Adolescente , Pruebas Genéticas/tendencias , Geografía Médica/métodos , Humanos , Recién Nacido , Jamaica/epidemiología , Epidemiología Molecular , Diagnóstico Prenatal , Adulto JovenRESUMEN
Durante el desarrollo de un individuo se expresan distintas cadenas de globina de tipo a y no-a, que se combinan en tetrámeros para formar hemoglobina. Los genes que las codifican se organizan en familias. Distintas mutaciones afectan los genes que codifican las cadenas de globina: si provocan alteraciones cualitativas originan cuadros de hemoglobinopatías estructurales, si disminuyen las síntesis de las cadenas de globina, talasemias, y si tienen ambos efectos, hemoglobinopatías talasémicas. El propósito de este trabajo es presentar las bases moleculares de las hemoglobinopatías en Argentina, en un total de 862 muestras, en base a los estudios moleculares realizados en este laboratorio a partir del estudio de 910 muestras de pacientes. En nuestro medio, la Hb S es la hemoglobinopatía estructural más frecuente, las ß-talasemias presentan una distribución similar a la cuenca del Mediterráneo y las a-talasemias están intrínsecamente relacionadas a la ascendencia de los afectados. Las bases moleculares de las hemoglobinopatías son variadas. Mientras que en las hemoglobinopatías estructurales y ß-talasemias predominan las mutaciones puntuales, en las a-talasemias predominan las deleciones. Se describen mutaciones nóveles (cambios puntuales, deleciones y duplicaciones) que se presentan como eventos aislados con herencia recesiva o dominante. Es necesaria la interacción entre el médico hematólogo, el laboratorio bioquímico, el laboratorio molecular y el médico genetista, para llegar al diagnóstico certero de estos cuadros que permitirán reducir la incidencia de las formas severas.
Functional hemoglobin is a tetramer composed of 2 a and 2 non-a chains, encoded by genes that are organized in clusters and are expressed sequentially through development. There are multiple mutations described that affect these genes: if the sequence variant leads to a qualitative alteration, the resulting effect is a structural hemoglobinopathy, if it decreases the synthesis of the globin chains, thalassemia, and if it affects both the quality and quantity of the globin chain, the consequence is a thalassemic hemoglobinopathy. The aim of this paper is to present the molecular bases of hemoglobinopathies in Argentina, determined in 862 patients, based on the results of the molecular studies carried out in our laboratory from the analysis of 910 samples. Hb S is the most frequent structural hemoglobinopathy, ß-thalassemia mutations exhibit a pattern similar to the one displayed by Mediterranean basin populations, and a-thalassemia mutations are intrinsically related to the ancestry of those affected. These syndromes exhibit diverse molecular bases: structural hemoglobinopathies and ß-thalassemia are a consequence, mostly of point mutations, whereas in a-thalassemia deletions prevail. Novel mutations (point changes, deletions and duplications) that occurred as isolated events, with recessive or dominant inheritance, were described. Interaction between the hematologist, the geneticist and both the clinical and molecular biology laboratories is necessary to reach an accurate diagnosis of these syndromes and reduce the incidence of severe forms.
Durante o desenvolvimento de um indivíduo expressam-se diversas cadeias de globina de tipo a e não-a, que se combinam em tetrámeros para formar hemoglobina. Os genes que as codificam são organizados em famílias. Diferentes mutações afetam os genes que codificam as cadeias de globina: se provocarem alterações qualitativas originam quadros de hemoglobinopatias estruturais, se diminuírem as sínteses das cadeias de globina, talassemias, e se tiverem ambos os efeitos, hemoglobinopatias talassêmicas. O propósito deste trabalho é apresentar as bases moleculares das hemoglobinopatias na Argentina, num total de 862 amostras, com base nos estudos moleculares realizados neste laboratório a partir do estudo de 910 amostras de pacientes. No nosso meio, a Hb S é a hemoglobinopatia estrutural mais frequente, as ß-talassemias apresentam uma distribuição similar à bacia do Mediterrâneo e as a-talassemias estão intrinsecamente relacionadas com a ascendência dos afetados. As bases moleculares das hemoglobinopatias são variadas. Enquanto nas hemoglobinopatias estruturais e ß-talassemias predominam as mutações pontuais, nas a-talassemias predominam as deleções. Descrevem-se mutações incipientes (mudanças pontuais, deleções e duplicações) que se apresentam como eventos isolados com herança recessiva ou dominante. É necessária a interação entre o médico hematólogo, o laboratório bioquímico, o laboratório molecular e o médico geneticista, para chegar ao diagnóstico certo desses quadros que permitirão reduzir a incidência das formas severas.
Asunto(s)
Humanos , Hemoglobinas/análisis , Hemoglobinopatías , Hemoglobinopatías/diagnóstico , Argentina , Talasemia , HemoglobinasRESUMEN
INTRODUCTION: Beta-thalassemia (ß-thal) is frequent in Mexican patients with microcytosis and hypochromia. We report three novel mutations and analyze the actual mutational spectrum in Mexican population. METHODS: One hundred and forty-nine ß-thal Mexican mestizo patients were studied (154 alleles). ARMS-PCR was performed to identify Cd39C>T, IVS1:1G>A, IVS1:110G>A, -28A>C, initiation codonA>G and IVS1:5G>A mutations, and gap-PCR for δß-thal Spanish type. DNA sequencing of HBB gene was carried out in negative samples for the initial screening. RESULTS: Fifteen different HBB gene mutations were observed in 148 alleles; three of them are novel: -90C>G, 20 bp deletion (at codons 78/85), and IVS2:2T>G; the mutation IVS1:6T>C that was observed for first time in our population; and eleven previously described mutations. Six alleles showed normal HBB sequence. To date, a total of 21 different mutations have been observed in Mexican patients; the four most frequent mutations are of Mediterranean origin: Cd39C>T (37.2%), IVS1:1G>A (17.3%), IVS1:110G>A (13.9%), and δß-thal Spanish type (9.0%), which represent 77.4% of the total studied alleles. CONCLUSION: Considering the novel mutations -90C>G, -20 bp Cd78/85, IVS2:2T>G and the first observation of IVS1:6T>C, the molecular spectrum of ß-thal in Mexicans comprises 21 different mutations, confirming the high allelic heterogeneity in Mexicans.
Asunto(s)
Alelos , Mutación , Globinas beta/genética , Talasemia beta/genética , Adolescente , Adulto , Anciano , Niño , Preescolar , Codón , Análisis Mutacional de ADN , Exones , Femenino , Heterogeneidad Genética , Genotipo , Humanos , Lactante , Intrones , Masculino , México , Persona de Mediana Edad , Análisis de Secuencia de ADN , Adulto JovenRESUMEN
ß-Thalassemia (ß-thal) is a hemolytic anemia that is caused by point mutations in most cases. The Brazilian population is highly heterogeneous and knowledge of the mutations that make up the genotypic profile of individuals can contribute information about the formation of the population and clinical condition of patients. In this study, we evaluated the mutations present in homozygous ß-thal patients from Rio de Janeiro, Brazil. We analyzed 24 samples of peripheral blood of patients with homozygous ß-thal. To identify the mutations, we carried out allele-specific-polymerase chain reaction (AS-PCR) and DNA sequencing. We found 11 different mutations on the ß-globin gene. Among the most frequent mutations observed were HBB: c.92 + 6T>C, followed by HBB: c.93-21G>A, HBB: c.118C>T and HBB: c.92 + 1G>A. We also identified the rare mutation HBB: c.75T>A that was reported in an individual carrying Hb S (HBB: c.20A>T)/ß-thal (HBB: c.75T>A) but not in Brazilian thalassemic patients, thus, this is the first report of this mutation in Brazilian ß-thal patients. For its multiethnic character, Brazil has different mutations that cause ß-thal and that are distributed with different frequencies according to the regions of the country. Our findings contribute to the description of the mutational profile of Brazilian thalassemic patients, showing wide heterogeneity and genetic variability.
Asunto(s)
Mutación , Globinas beta/genética , Talasemia beta/genética , Adolescente , Adulto , Alelos , Brasil/epidemiología , Niño , Codón , Análisis Mutacional de ADN , Exones , Femenino , Frecuencia de los Genes , Estudios de Asociación Genética , Predisposición Genética a la Enfermedad , Genotipo , Humanos , Intrones , Masculino , Persona de Mediana Edad , Fenotipo , Regiones Promotoras Genéticas , Adulto Joven , Talasemia beta/diagnóstico , Talasemia beta/epidemiología , Talasemia beta/terapiaRESUMEN
INTRODUCTION: Alpha-thalassemia (α-thal) is a common monogenic disorder worldwide. In mixed ethnic populations, α-thal and beta-thalassemia (ß-thal) can be expected, sometimes giving complex phenotypes, which without molecular analysis are not easily explained. We performed the molecular identification of α- and ß-thal alleles in 51 Mexican patients with microcytosis, hypochromia, and normal or low levels of HbA2 . METHODS: Common deletional alleles (-α(3.7) , -α(4.2) , - -(SEA) , - -(MED) , - -(FIL) , - -(THAI) , -α(20.5) ) and α-triplication were studied by gap-PCR and nondeletional alleles (α(IVSI) ((-5nt)) , α2 (NcoI) , α1 (NcoI) ) by ARMS. ß-thal alleles Cd39 (C>T), IVS1:1 (G>A), IVS1:110 (G>A), and Spanish δß-thal were also investigated. DNA sequencing was performed on HBA2, HBA1, and HBB genes. Negative samples were subjected to MLPA. RESULTS: In 35 subjects, we identified the mutations, -α(3.7) , - -(SEA) , - -(FIL) , α(IVSI) ((-5nt)) , and ααα(anti3.7) and two novel deletion alleles - -(Mex1) (6.8-8.9 kb) and - -(Mex2) (77.6-135.7 kb). Four individuals also had a ß-thal allele (Cd39/IVS1:110). No α-thal alleles were observed in 16 subjects, but three had a ß-thal mutation Cd39, IVS1:110, and Spanish δß-thal. CONCLUSION: α-thal is relatively common in Mexican patients, the combination with ß-thal is sometimes unexpected, and this underlines the importance of performing molecular analysis for both α- and ß-genes defects in patients showing microcytic hypochromic anemia.
Asunto(s)
Alelos , Anemia Hipocrómica/genética , Secuencia de Bases , Hemoglobina Glucada/genética , Hemoglobinas Anormales/genética , Eliminación de Secuencia , Talasemia alfa/genética , Talasemia beta/genética , Femenino , Humanos , Masculino , MéxicoRESUMEN
OBJECTIVES: In sickle cell/ß-thalassemia, mutations in the corresponding ß-globin genes are responsible for complex pathological events resulting in diverse clinical complications. The objective of this study was to provide an overview of the clinical and laboratory characteristics of patients with the syndrome, and of the degree of severity of clinical manifestations resulting from the ß-thalassemia mutation. METHODS: A retrospective chart review was performed on 46 patients with sickle cell/ß-thalassemia (31 Sß° and 15 Sß+), evaluating hematological parameters and end organ damage. Statistical analyzes were carried out in order to highlight differences between the two groups according to the nature of the thalassemia mutation. RESULTS: As expected, patients with the Sß0 phenotype had a higher degree of hematological involvement in comparison to Sß+ patients; with lower hemoglobin levels, and signs of more intense chronic hemolysis. However, Sß+ patients were more prone to the occurrence of acute chest syndrome. The impact of the thalassemia mutation upon total body and bone composition was also evident, as Sß0 patients presented lower body mass index (BMI) and bone mineral density. The degree of bone damage correlated to lower BMI and hemoglobin levels, as well as plaquetosis, monocytosis and elevated lactate dehydrogenase, possibly reflecting the effects of hemolysis and inflammation upon bone metabolism and body constitution. CONCLUSIONS: This study identified significant differences among sickle cell/ß-thalassemia patients according to the beta mutation involvement, pointing to an important predictor of disease severity.
Asunto(s)
Anemia de Células Falciformes/complicaciones , Hemoglobina Falciforme/genética , Talasemia beta/genética , Adolescente , Adulto , Anciano , Anemia de Células Falciformes/sangre , Brasil , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Adulto Joven , Globinas beta/genética , Talasemia beta/sangreRESUMEN
The spectrum of ß-thalassemia (ß-thal) mutations was investigated for the first time in a cohort of 33 unrelated patients from the Brazilian Amazon attending the Center for Hemotherapy and Hematology of the Pará Foundation (HEMOPA), in Belém, the state capital of Pará, Northern Brazil. Identification of the ß-thal mutations was made by direct genomic sequencing of the ß-globin gene. Mutations were identified in all patients, corresponding to a spectrum of 10 different point mutations and a total of 37 alleles studied. HBB: c.92 + 5G > A [IVS-I-5 (G > A)], was the most common ß-thal mutation, followed by HBB: c.118C > T [codon 39 (C > T)], HBB: c.-138C > T [-88 (C>T)], HBB: c.92 + 1G > A [IVS-I-1 (G > A)] and HBB: c.92 + 6T > C [IVS-I-6 (T > C)] mutations. These five mutations (four Mediterranean origin and one African origin) accounted for 86.5% of the ß-thal alleles. The profile of ß-thal mutations found in northern Brazil is different from those described in other regions of the country. In the southeast and south, the nonsense mutation HBB: c.118C > T is the most prevalent, followed by HBB: c.93-21G > A [IVS-I-110 (G > A)], whereas in the northeast, HBB: c.92 + 6T > C has been identified as the most common mutation, followed by HBB: c.92 + 1G > A. This heterogeneous geographical distribution is certainly related to the ancestry of Brazilian populations because they have similar genetic backgrounds (European, African and Amerindian), although with slightly different admixture proportions. Furthermore, the European contribution in the southeast and south was largely made up of immigrants of other nationalities, such as Italian and Spanish, in addition to Portuguese.
Asunto(s)
Mutación Puntual , Globinas beta/genética , Talasemia beta/epidemiología , Talasemia beta/genética , Adulto , Brasil/epidemiología , Estudios de Cohortes , Femenino , Frecuencia de los Genes , Humanos , Masculino , Adulto JovenRESUMEN
Introdução: A deficiência de ferro é frequente entre mulheres na idade reprodutiva e é considerada problema de saúde pública mundial. Por outro lado, patologias associadas com aumentada atividade eritropoética e sobrecarga de ferro, como as talassemias e a anemia falciforme, estão entre as doenças monogênicas mais frequentes em muitas populações. Os genes HFE e TMPRSS6 codificam as proteínas hemocromatose hereditária (HFE) e matriptase-2 (MT2) que, no fígado, modulam a produção de hepcidina, o hormônio regulador central do metabolismo de ferro. O objetivo deste estudo foi avaliar a relação entre o consumo alimentar de ferro, as variantes rs855791 (MT2736V), rs4820268 (MT2521V), rs1799945 (HFE63D) e rs1800562 (HFE282Y) e o status corporal do mineral entre mulheres com atividade eritropoética normal (aparentemente saudáveis) ou levemente aumentada (com ß-talassemia menor). Casuística e métodos: Inicialmente, foram incluídas 127 estudantes universitárias na idade reprodutiva (18 a 42 anos) e em aparente balanço estacionário do ferro corporal (necessidades fisiológicas e consumo alimentar de ferro pouco variáveis há pelo menos 12 meses). Em um segundo estudo, foram incluídos 33 casos de ß-talassemia menor (18 na pós-menopausa), registrados em serviços de hematologia de dois hospitais de São Paulo-SP e um de Sorocaba-SP. Essas foram pareadas com 66 controles, segundo idade, índice de massa corporal, status reprodutivo e uso de anticoncepcionais hormonais. A partir de inquéritos feitos com registros alimentares ou recordatórios de 24 horas foi estimado o consumo de ferro total e biodisponível. Amostras de sangue foram utilizadas para a extração de DNA e determinações de ferritina sérica, saturação da transferrina e hemoglobina. As genotipagens do TMPRSS6 e do HFE foram realizadas por PCR em tempo real. Resultados: Considerando as 226 mulheres avaliadas, as frequências dos alelos MT2736V, MT2521D, HFE63D e HFE282Y foram estimadas em 40,3%, 44,0%, 16,3% e 1,5% respectivamente. No primeiro estudo, foi estimada média de consumo de ferro 10 de 10,9 mg/dia e prevalência de deficiência do mineral de 12,6%. Estimativas de consumo de ferro biodisponível, mas não de ferro total, foram correlacionadas com os valores de ferritina e saturação da transferrina. As associações entre a biodisponibilidade dietética de ferro e seus biomarcadores foram especialmente evidentes entre as carreadoras da variante HFE63D, indicando uma significante interação gene-nutriente. Por outro lado, valores relativamente menores de saturação da transferrina foram associados à presença do alelo MT2736V, independentemente do consumo de ferro biodisponível. Mulheres com ß-talassemia menor e suas controles não diferiram quanto à frequência das variantes TMPRSS6 e HFE ou à biodisponibilidade dietética de ferro. Na pós-menopausa, a ß-talassemia menor foi associada com valores duas vezes maiores de ferritina, 20% maiores de saturação da transferrina e com probabilidade 3,5 vezes maior de hiperferritinemia. Entretanto, para casos e controles na idade reprodutiva, foi estimada probabilidade de inadequação do consumo de 20,7% e prevalências de deficiência do mineral de 13,3% e 10,0%, respectivamente. Entre essas mulheres, o genótipo positivo ou negativo para a variante MT2736V foi também associado com diferenças nas médias de saturação da transferrina. No entanto, o contraste nesses valores foi relativamente maior entre as mulheres com ß-talassemia menor. Além disso, mais acentuada hipocromia acompanhou a presença da variante MT2736V nessa condição. Conclusão: Os achados sugerem que, entre mulheres com eritropoese normal ou com ß-talassemia menor, a variante MT2736V não afeta tão fortemente as reservas de ferro corporal como faz a adequação do consumo desse mineral. Ainda assim, a variante HFE63D pode modificar a relação da biodisponibilidade de ferro com seu status corporal e, portanto, ser um importante marcador preditivo de resposta diferencial à dieta. A variante MT2736V foi associada com menor disponibilidade de ferro na circulação de mulheres na idade reprodutiva e, entre aquelas com ß.;-talassemia menor, com indício de acentuada alteração morfológica dos eritrócitos
Introduction: Iron deficiency is common among women at childbearing age and it is regarded as a worldwide public health issue. On the other hand, disorders associated with increased erythropoietic activity and iron overload, such as thalassemias and sickle cell disease, are among the most frequent Mendelian diseases in many populations. HFE and TMPRSS6 genes encode the hereditary hemochromatosis protein (HFE) and the matriptase-2 (MT2) both of which modulate the hepatic production of hepcidin, the main hormone regulator of iron metabolism. The aim of this study was to evaluate the relationship among dietary iron intake, rs855791 (MT2736V), rs4820268 (MT2521D), rs1799945 (HFE63D) and rs1800562 (HFE282Y) genetic variants and body iron status of women with normal (apparently healthy) or slightly increased (ß-thalassemia minor) erythropoietic activity. Casuistic and methods: Initially, 127 university students at childbearing age (18 to 42 years old) and with steady state body iron (few variations on physiological requirements and dietary iron intake at least for the last 12 months) were included. In a second study, it was included 33 cases of ß-thalassemia minor (18 of them post-menopaused) registered in Hematology Services from two hospitals from São Paulo-SP and one from Sorocaba-SP. They were paired with 66 controls by age, body mass index, reproductive status and hormonal contraceptive use. Using food diaries or 24 hours food recalls, total and bioavailable dietary iron intakes were estimated. Blood samples were used for DNA extraction and for determinations of ferritin, transferrin saturation with iron and hemoglobin. TMPRSS6 and HFE genotyping were performed by real time PCR. Results: Considering all the 226 women studied, the allelic frequencies of MT2736V, MT2521D, HFE63D e HFE282Y genetic variants were em 40.3%, 44.0%, 16.3% e 1.5%, respectively. In the first study, a total dietary iron intake of 10.9 mg/day and an iron deficiency prevalence of 12.6% were estimated. There were correlations among ferritin and transferrin saturation values with estimates of bioavailable, but not of total dietary iron intake s. Associations between dietary iron bioavailability and iron biomarkers were especially evident among carriers of HFE63D variant, indicating a significant gene-diet interaction. On the other hand, lower levels of transferrin saturation were associated with the presence of MT2736V variant allele, irrespective of bioavailable iron intake. TMPRSS6 and HFE variants frequencies and dietary iron bioavailability estimates did not differ between women with ß-thalassemia minor and their controls. Among postmenopausal women, ß-thalassemia minor was associated with two times higher ferritin values, 20% higher transferrin saturation values and 3.5 times higher chance for hiperferritinemia. However, among cases and controls at childbearing age, it was estimated a probability of inadequacy in the dietary iron intake of 20.7% and iron deficiency prevalences of 13.3% and 10.0%, respectively. Among these women, a positive or negative genotype for MT2736V was also associated with differences in transferrin saturation. Nevertheless, the contrast between these values was relatively higher among women with ß-thalassemia minor. Moreover, a more accentuated hypochromia accompanied the presence of the MT2736V variant in this condition. Conclusions: Our findings suggest that, among women with normal erythropoiesis or ß-thalassemia minor, the presence of the MT2736V variant does not strongly impact the body iron stores as does dietary iron adequacy. Nevertheless, the HFE63D variant may modify the relationship between the dietary iron bioavailability and the body iron status. Therefore, it might be an important predictive marker of women's differential response to diet. The MT2736V variant was associated with lower availability of circulating iron in women at childbearing age and, among those with ß-thalassemia minor, with suggestive accentuated morphological alteration of erythrocytes
Asunto(s)
Humanos , Femenino , Adolescente , Adulto , /complicaciones , Disponibilidad Biológica , Eritropoyesis , Talasemia beta/tratamiento farmacológico , GenesRESUMEN
ß-Thalassemia intermedia (ß-TI) patients present with a wide spectrum of phenotypes depending on the presence of primary, secondary, and tertiary genetic modifiers which modulate, by different mechanisms, the degree of imbalance between α and ß chains. Here we describe a new ß(0) frameshift mutation, HBB: c.44delT (p.Leu14ArgfsX5), identified in four members of a family, associated with secondary genetic modifiers in three of them. The different genotype present in this family was suspected after hematological analysis and thorough observation of blood smears highlighting their importance in the identification of ß-TI patients among members of the same family.
Asunto(s)
Familia , Mutación del Sistema de Lectura , Genes Modificadores , Hemoglobinas Anormales/genética , Globinas beta/genética , Talasemia beta/genética , Adulto , Argentina , Femenino , Humanos , MasculinoRESUMEN
The main hereditary hemoglobin (Hb) disorder in Argentina is ß-thalassemia (ß-thal). Molecular studies performed in the center of the country exhibited a marked prevalence of the codon 39 (C > T) and IVS-I-110 (G > A) mutations. The northwest region of Argentina has a different demographic history characterized by an important Spanish influx. Seventy-one ß-thal carriers attending the Instituto de Bioquímica Aplicada, Tucumán, Argentina, were investigated for ß-globin gene mutations by real-time polymerase chain reaction (RT-PCR). To examine the genotype-phenotype relationship, mean corpuscular volume (MCV), mean corpuscular Hb (MCH) and Hb A2 were measured. In order to recognize ß-thal, Mentzer Index, Shine & Lal and Red Cell Distribution Width Index (RDWI), were calculated. The ethnic background of subjects revealed that 82.0% of the population was of Italian, Spanish and Arab origin. Seven mutations were detected: codon 39 (45.0%), IVS-I-1 (G > A) (22.5%), IVS-I-110 (16.3%), IVS-II-1 (G > A) (4.1%), IVS-I-1 (G > T) (2.0%), IVS-I-6 (T > C) (2.0%) and IVS-II-745 (G > C) (2.0%). In three families (6.1%), ß-thal mutations were not determined. These results differed from other Argentinian studies because at present codon 39 and IVS-I-1 are the most prevalent; MCV, MCH and Hb A2 did not correlate with the type of mutation (ß(0)/ß(+)). Values of MCV (67.0 fL) and Hb A2 (4.85%) were unable to discriminate between them. Significant differences (p < 0.05) in MCV, MCH and Shine & Lal were observed between the undetermined group and the three most common mutations. These data show different patterns of ß-thal mutations in the center and northwest regions of Argentina. Differences might represent the influence of Spanish immigration.